Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data shows avelumab helps control advanced bladder cancer after chemo

NCT ID NCT05366725

Disease control Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 106 adults with advanced bladder cancer that hadn't gotten worse after initial chemotherapy. They received avelumab as a maintenance treatment to help keep the cancer under control. Researchers tracked how long patients lived and any side effects in real-world settings over about 4 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

106 people

The number who actually took part.

Started

Jun 2022

Finished

Jun 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with a diagnosis of locally advanced or metastatic UC, either de novo or relapsed who are progression-free following completion of platinum-based chemotherapy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with a diagnosis of locally advanced or metastatic UC, either de novo or relapsed 2. Patients received 1L platinum-based chemotherapy and had stable disease, partial response, or complete response to this treatment 3. Patients received avelumab as indicated as a monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic UC who are progression-free following platinum-based chemotherapy 4. Patients aged ≥18 years on the date that they commenced avelumab - Exclusion Criteria: 1. Patients whose hospital records are not available for review 2. Patients who are receiving an investigational medicinal product as part of a clinical trial at the time of maintenance therapy with avelumab

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced or metastatic urothelial carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Urothelial cancer

Contacts and locations

Locations

  • Beatson West of Scotland Cancer Centre

    Glasgow, G12 0YN, United Kingdom

  • Churchill Hospital

    Oxford, OX3 7LE, United Kingdom

  • Clatterbridge Hospital

    Metropolitan Borough of Wirral, CH63 4JY, United Kingdom

  • Guy's and St Thomas' Hospital

    London, SE1 9RT, United Kingdom

  • Lister Hospital

    Stevenage, SG1 4AB, United Kingdom

  • Royal Preston Hospital

    Preston, PR2 9HT, United Kingdom

  • Royal Surrey County Hospital

    Guildford, GU2 7XX, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • University College London Hospital

    London, NW1 2PG, United Kingdom

  • University Hospitals Bristol

    Bristol, BS1 3NU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.